Pharmaceutical Research and Manufacturers of America v. Federal Trade Commission
44 F. Supp. 3d 95
D.D.C.2014Background
- PhRMA challenged FTC Final Rule applying reporting to pharmaceutical patent license transfers under HSR Act §7A(a).
- Rule defines all commercially significant rights, limited manufacturing rights, and co-rights and restricts coverage to NAICS 3254 pharma industry.
- FTC invoked 15 U.S.C. §18a(d)(1)-(2) to define terms and tailor exemptions, claiming industry-specific rule is permissible.
- NPRM proposed the new definitions; final rule issued Nov 15, 2013, effective Dec 16, 2013, unchanged from NPRM.
- PhRMA alleged the rule exceeds statutory authority, is arbitrary and capricious, and violates required rulemaking procedures; FTC moved for summary judgment; court denied PhRMA, granted FTC.
- The court evaluated Chevron Step One and Two, statutory text and history, and administrative record, applying deferential review.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether FTC may issue industry-specific premerger rules | PhRMA argues no direct grant to tailor coverage by industry; uniform application required | FTC contends authority to define terms and tailor rules; industry-specific allowed | FTC's industry-specific rule upheld under Chevron Step Two |
| Whether HSR Act allows selective industry coverage | No express directive allowing selective coverage; would exceed statutory language | Statute authorizes exemptions and broad rulemaking; not bound to uniform coverage | Congress did not directly address industry-specific rules; deference to agency construction under Chevron applied |
| Whether Final Rule is a reasonable interpretation of the statute | Rule rests on agency expertise but lacks rational basis; selective industry targeting unsupported | Rule is rational, tailored to evolving pharma licensing structures; supported by data and experience | Court found a rational basis for the rule and sustained agency’s interpretation |
| Whether agency record and procedural requirements were satisfied | FTC failed to provide sufficient rulemaking record; relied on confidential filings and informal interpretations | Public NPRM, public database, and post-comment discussions provided adequate basis; confidentiality of some filings acceptable | Rulemaking procedures satisfied; Final Rule valid under APA |
| Whether FTC’s incremental, pharma-specific approach was permissible | Incremental targeting contravenes uniform application and oversteps authority | Incremental approach allows targeted, necessary regulation; not prohibited by statute | Incremental, industry-specific approach permissible under the statute |
Key Cases Cited
- Mattox v. FTC, 752 F.2d 116 (5th Cir. 1985) (HSR purpose and premerger review relevance)
- Environmental Defense Fund, Inc. v. EPA, 82 F.3d 451 (D.C. Cir. 1996) (statutory interpretation and exemptions supportive of agency discretion)
- Seven-Up Bottling Co. of Miami v. NLRB, 344 U.S. 344 (Supreme Court 1953) (agency experience as basis for decisionmaking evidence admissibility)
- Verizon v. FCC, 740 F.3d 623 (D.C. Cir. 2014) (Chevron deference in agency interpretations of ambiguous statutes)
- State Farm Mut. Auto. Ins. Co. v. State Farm, 463 U.S. 29 (Supreme Court 1983) (arbitrary and capricious standard requires rational connection)
- City of Arlington, Tex. v. FCC, 133 S. Ct. 1863 (2013) (Chevron Step Two deference to agency rule interpretations)
- United States v. Home Concrete & Supply, LLC, 132 S. Ct. 1836 (Supreme Court 2012) (statutory interpretation and deference considerations)